Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
将临床阶段化合物的抗肿瘤作用机制定义为核孔复合物的选择性降解剂。
期刊:Cancer Discovery
影响因子:29.7
doi:10.1158/2159-8290.CD-25-0271
Linjie Yuan,Wenzhi Ji,Brendan G Dwyer,Joey Lu,Jing Bian,Gianna M Colombo,Michael J Martinez,Daniel Fernandez,Nick A Phillips,Michelle T Tang,Christine Wenjie Zhou,Nirk E Quispe Calla,Cesar Guzman Huancas,Michael Eckart,Jessica Tran,Hannah M Jones,Tian Qiu,John G Doench,Matthew G Rees,Jennifer A Roth,Michael D Cameron,Gregory W Charville,Calvin J Kuo,Scott J Dixon,Tinghu Zhang,Stephen M Hinshaw,Nathanael S Gray,Steven M Corsello